ALX Oncology appoints Jeff Knight as Chief Development and Operating Officer

ALX ONCOLOGY HOLDINGS INC

Jeff Knight, former CDOO at Crinetics, appointed effective April 13, 2026; role includes clinical development and operations.
Compensation: $565k base salary, 40% annual target bonus, and stock option for 800k shares under 2025 Inducement Plan.
Knight brings 30+ years experience; previously at Poseida, Halozyme, Amgen, and Genentech.
Company highlights upcoming catalysts for evorpacept and ALX2004 programs in next 12-18 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.